Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nutex Health (NUTX) Current Deferred Revenue (2016 - 2022)

Nutex Health's Current Deferred Revenue history spans 9 years, with the latest figure at $92111.0 for Q1 2022.

  • For Q1 2022, Current Deferred Revenue rose 71.09% year-over-year to $92111.0; the TTM value through Mar 2022 reached $92111.0, up 71.09%, while the annual FY2021 figure was $173919.0, 126.79% up from the prior year.
  • Current Deferred Revenue for Q1 2022 was $92111.0 at Nutex Health, down from $173919.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $173919.0 in Q4 2021 and bottomed at $600.0 in Q3 2019.
  • The 5-year median for Current Deferred Revenue is $40217.0 (2020), against an average of $52588.6.
  • The largest annual shift saw Current Deferred Revenue crashed 85.6% in 2019 before it surged 2743.67% in 2020.
  • A 5-year view of Current Deferred Revenue shows it stood at $4167.0 in 2018, then soared by 3873.12% to $165560.0 in 2019, then tumbled by 53.68% to $76687.0 in 2020, then surged by 126.79% to $173919.0 in 2021, then tumbled by 47.04% to $92111.0 in 2022.
  • Per Business Quant, the three most recent readings for NUTX's Current Deferred Revenue are $92111.0 (Q1 2022), $173919.0 (Q4 2021), and $45022.0 (Q3 2021).